Alector, Inc. (NASDAQ:ALEC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Alector in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($2.55) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share.
Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.10. The firm had revenue of $15.34 million for the quarter, compared to analysts' expectations of $16.33 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%.
ALEC has been the subject of several other reports. Mizuho downgraded shares of Alector from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $9.00 to $2.50 in a research note on Tuesday, December 17th. Bank of America lowered Alector from a "neutral" rating to an "underperform" rating and cut their price objective for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. BTIG Research decreased their target price on Alector from $16.00 to $5.00 and set a "buy" rating for the company in a research report on Tuesday, November 26th. HC Wainwright dropped their target price on Alector from $35.00 to $7.00 and set a "buy" rating on the stock in a report on Friday, November 29th. Finally, Stifel Nicolaus downgraded shares of Alector from a "buy" rating to a "hold" rating and set a $4.00 price objective for the company. in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Alector presently has an average rating of "Hold" and a consensus target price of $3.75.
Read Our Latest Stock Analysis on ALEC
NASDAQ ALEC opened at $1.73 on Wednesday. Alector has a 1-year low of $1.60 and a 1-year high of $7.58. The firm has a market capitalization of $169.42 million, a P/E ratio of -1.02 and a beta of 0.57. The business's 50-day simple moving average is $2.46 and its 200-day simple moving average is $4.27.
A number of hedge funds have recently made changes to their positions in ALEC. SG Americas Securities LLC raised its stake in Alector by 27.9% during the 4th quarter. SG Americas Securities LLC now owns 39,334 shares of the company's stock valued at $74,000 after acquiring an additional 8,581 shares in the last quarter. Nordea Investment Management AB grew its position in Alector by 5.1% in the 4th quarter. Nordea Investment Management AB now owns 165,713 shares of the company's stock valued at $295,000 after buying an additional 7,971 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company's stock valued at $12,716,000 after buying an additional 1,072,298 shares during the period. Barclays PLC lifted its stake in shares of Alector by 132.4% in the 3rd quarter. Barclays PLC now owns 176,800 shares of the company's stock worth $824,000 after acquiring an additional 100,731 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Alector by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company's stock valued at $8,874,000 after acquiring an additional 148,357 shares in the last quarter. Institutional investors own 85.83% of the company's stock.
In related news, insider Sara Kenkare-Mitra sold 26,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $2.52, for a total transaction of $66,780.00. Following the sale, the insider now owns 565,215 shares in the company, valued at $1,424,341.80. This represents a 4.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Arnon Rosenthal sold 52,172 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total value of $131,473.44. Following the sale, the chief executive officer now owns 2,507,074 shares in the company, valued at $6,317,826.48. The trade was a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 95,161 shares of company stock worth $239,806. Insiders own 9.10% of the company's stock.
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alector, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.
While Alector currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.